Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News (Page 4)
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Cancer Screening Has Provided Significant Value to U.S. Population
TUESDAY, Aug. 22, 2023 – Cancer screening has provided significant value to the U.S. population, and improved adherence would add more value, according to a study published online Aug. 7 in BMC...
FDA Grants Regular Approval for Gavreto (pralsetinib) for Non-Small Cell Lung Cancer with RET Gene Fusions
On August 9, 2023, the Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET)...
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
TUESDAY, Aug. 15, 2023 – For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall...
Plasma ctDNA Genotyping Can Accelerate Time to Treatment for NSCLC
FRIDAY, July 28, 2023 – For patients with suspected advanced non-small cell lung cancer (NSCLC), plasma circulating tumor (ct)DNA genotyping before tissue diagnosis is associated with accelerated...
New Report Measures Scope of Damage From Medical Mistakes
THURSDAY, July 20, 2023 – About 795,000 Americans die or are permanently disabled every year due to misdiagnosed medical conditions. A new analysis led by experts at Johns Hopkins Medicine in...
Adherence to Global Health Recommendations Cuts Risk for Some Cancers
TUESDAY, July 18, 2023 – Greater adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations is associated with a lower risk for breast,...
Blood-Based Marker Plus PLCO Risk Model Can ID Lethal Lung Cancer
THURSDAY, July 13, 2023 – A blood-based biomarker panel combined with the Prostate, Lung, Colorectal, and Ovarian (PLCO) risk model (PLCOm2012) can identify individuals at high risk of lethal lung...
2019 to 2021 Saw Rise in Lung Cancer Screenings
THURSDAY, June 22, 2023 – The prevalence of lung cancer screening (LCS) increased in 2021 versus 2019, according to a research letter published online June 21 in JAMA Network Open. Kristin G. Maki,...
American Society of Clinical Oncology, June 2-6
The annual meeting of the American Society of Clinical Oncology was held from June 2 to 6 in Chicago and attracted more than 34,000 participants from around the world, including clinicians,...
Fewer Black Veterans Complete Referrals for Lung Cancer Screening
FRIDAY, June 16, 2023 – Black veterans have significantly lower odds of completing lung cancer screening (LCS) than White veterans even after adjusting for demographic and socioeconomic risk...
Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug, Alecensa
WEDNESDAY, June 14, 2023 – The lung cancer drug alectinib (Alecensa) is more potent when taken with a fuller breakfast, or lunch, than when taken with a low-fat breakfast, researchers report. The...
Alectinib Exposure Lower With Low-Fat Yogurt Intake
WEDNESDAY, June 14, 2023 – For patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer, alectinib exposure is lower when taken with low-fat yogurt, according to a study...
2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
FRIDAY, June 9, 2023 – For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors. But...
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
TUESDAY, June 6, 2023 – For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for...
Gene-Targeted Drug Tagrisso Cuts Death Rate in Half for Patients With Early-Stage Lung Cancer
TUESDAY, June 6, 2023 – Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical...
Ask a question
To post your own question to this support group, sign in or create an account.